Source: rafapress / Shutterstock.com
4D Molecular Therapeutics (NASDAQ:FDMT) just reported results for the first quarter of 2024.
- 4D Molecular Therapeutics reported earnings per share of -66 cents. This was above the analyst estimate for EPS of -74 cents.
- The company reported revenue of $28,000.
- This was 96.41% worse than the analyst estimate for revenue of $780,000.
Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/05/fdmt-stock-earnings-4d-molecular-therapeutics-for-q1-of-2024/.
©2024 InvestorPlace Media, LLC